Asset Details
Do you wish to reserve the book?
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Do you wish to request the book?
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
2008
Overview
In a 2-year clinical trial, the addition of ezetimibe to simvastatin had no effect on the progression of atherosclerosis, as measured by carotid-artery intima–media thickness, despite the additional lowering of levels of low-density lipoprotein cholesterol and C-reactive protein by ezetimibe when added to simvastatin. However, the study was not powered to assess clinical end points.
The addition of ezetimibe to simvastatin had no effect on the progression of atherosclerosis, as measured by carotid-artery intima–media thickness, despite the additional lowering of levels of low-density lipoprotein cholesterol and C-reactive protein.
A reduction in levels of low-density lipoprotein (LDL) cholesterol constitutes one of the cornerstones in the prevention of cardiovascular disease. In recent trials comparing various statins or the same statin at various doses, aggressive therapy to lower LDL cholesterol levels was associated with a reduction in rates of cardiovascular events.
1
–
4
However, administration of the highest approved statin dose offers only limited additional lowering of LDL cholesterol at the expense of an increased incidence of side effects.
5
Therefore, novel compounds that further reduce LDL cholesterol levels when added to statin therapy are of interest. A recently introduced compound, ezetimibe, selectively . . .
Publisher
Massachusetts Medical Society
Subject
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - therapeutic use
/ Azetidines - adverse effects
/ Azetidines - therapeutic use
/ Biological and medical sciences
/ Carotid Arteries - diagnostic imaging
/ Carotid Arteries - pathology
/ Diet
/ Disorders of blood lipids. Hyperlipoproteinemia
/ Female
/ Femoral Artery - diagnostic imaging
/ Humans
/ Hyperlipoproteinemia Type II - drug therapy
/ Hyperlipoproteinemia Type II - pathology
/ Male
/ Simvastatin - adverse effects
/ Simvastatin - therapeutic use
/ Statins
/ Tunica Intima - diagnostic imaging
